AlphAIalphai — Financial news for AI agents
finanznachrichten.deAUG 45 min read$XGN

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. (Nasdaq: XGN) reported Q2 2026 results for the quarter ended June 30. Total revenue rose to $19.9 million, up 16% year over year, with AVISE CTD test volume up 11% and trailing twelve-month ASP at $446. Adjusted EBITDA loss narrowed to $0.1 million. Full-year 2026 revenue guidance increased to $72 to $75 million.

Original reporting
finanznachrichten.de
Published Aug 4, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$XGN
Bullish
medium confidence
Mentioned
$XGN
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$XGNBullishMed
01

Why it matters

The key tradable elements are the raised FY2026 revenue guidance ($72M-$75M vs $70M-$73M), record Q2 revenue and test volume growth, higher trailing-twelve-month ASP, and a narrowed adjusted EBITDA loss to $0.1M.

02

Market read

A guidance raise paired with improved adjusted EBITDA and record revenue/test-volume metrics can shift expectations for operating leverage in a small-cap diagnostics name.

03

What to watch

The press release emphasizes non-GAAP adjusted EBITDA; traders may scrutinize GAAP operating loss trajectory, cash burn dynamics beyond ending cash, and whether ASP/test-volume gains are durable.

Relevance 8/10Novelty 8/10Timing: today, after-hours/next-session digestion of Q2 print and FY guidance raise

Background

Exagen is an autoimmune diagnostics company focused on AVISE CTD testing; this release covers Q2 2026 results and updated full-year guidance.

Company-level read

Ticker impact

$XGNBullishMedium confidence
Context

Exagen (XGN) reported Q2 results with record revenue of $19.9M, improved adjusted EBITDA loss to $0.1M, and raised FY2026 revenue guidance to $72M-$75M.

Expected impact

Likely positive bias for the stock into the next trading sessions as investors digest the raised revenue range and EBITDA narrowing.

Evidence & confidence

The article discloses multiple fresh, decision-relevant datapoints: Q2 revenue growth, ASP and test volume trends, adjusted EBITDA improvement, ending cash, and an explicit FY guidance raise. However, it is still a loss-making quarter, limiting conviction on sustained profitability timing.

Market effects

Sector

Supports sentiment for autoimmune diagnostics providers by highlighting real-world evidence and improving unit economics (ASP and adjusted EBITDA).

Regional

Limited, company-specific impact likely confined to small-cap biotech/diagnostics sentiment.

Global

Low; no cross-border regulatory or commercial deal details disclosed.

Counterpoint

What could challenge this read

Despite guidance lift, Exagen remains loss-making on GAAP net loss and adjusted EBITDA is still negative, so the market may demand proof of sustained cash generation before re-rating.

Key entities

  • company
    Exagen Inc.

    Nasdaq-listed autoimmune diagnostics provider reporting Q2 2026 results and raising FY2026 revenue guidance.

  • product
    AVISE CTD

    Flagship autoimmune testing offering referenced for test volume and ASP trends.

  • executive
    John Aballi

    CEO who commented on progress toward sustainable profitability and cash generation.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 6
$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

yahoo.com4 min
AUG 4
$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

yahoo.com6 min
AUG 4
$XGNMed

EXAGEN INC. (XGN): Results of Operations and Financial Condition

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026exagenearningspressr.htm EX-99.1 Document Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased

SEC EDGAR 8-K4 min
AUG 24
$IQMed

Form Video Industry Growth Logic Transformation in the AI Era

iQIYI reported Q2 2026 revenue of RMB 6.29 billion, with membership and advertising services contributing RMB 4.01 billion and RMB 1.25 billion, respectively. Non-GAAP operating loss narrowed. Key highlights include positive operating cash flow, 56% YoY growth in content distribution revenue, AI business progress, and 40% YoY growth in overseas membership revenue. The company is undergoing strategic transformation, focusing on AI and decentralization.

eu.36kr.com3 min